Patent Number: 
Section: claims

1. A composition for use in preparing radiopharmaceuticals comprising from 4 Ci to 15 Ci of copper-64 (64Cu) and having a specific activity of about 350 mCi 64Cu/μg Cu up to about 3800 mCi 64Cu/μg Cu. 2. The composition of claim 1, wherein the composition is obtained from a single cyclotron run. 3. The composition of claim 1, wherein the composition comprises from 4 Ci to 5 Ci of 64Cu at the end of bombardment (EOB) of a single cyclotron run of about 2 h to about 4 h. 4. The composition of claim 1, wherein the composition comprises from about 5 Ci to about 9 Ci of 64Cu at the end of bombardment (EOB) of a single cyclotron run of about 6 h. 5. The composition of claim 1, wherein the composition comprises from 4 Ci to 15 Ci of 64Cu at the end of bombardment (EOB) of a single cyclotron run of about 8 h to about 12 h. 6. The composition of claim 1, wherein the composition has a specific activity from about 350 mCi 64Cu/μg Cu to about 2300 mCi 64Cu/μg Cu. 7. The composition of claim 1, wherein the composition has a total content of trace metals of less than about 5 parts per million (ppm), the trace metals being cobalt, copper, gold, iron, lead, mercury, nickel, and zinc. 8. The composition of claim 1, wherein the composition comprises a solution of hydrochloric acid (HCI) having a molarity of about 0.001 M to about 3 M. 9. The composition of claim 7, wherein the molarity of the HCI is about 0.05 M. 10. The composition of claim 9, wherein the 64Cu exists as [64Cu]CuCl2. 11. The composition of claim 9, wherein the composition further comprises a chelating agent or a bifunctional chelating agent in which the 64Cu is coordinated therein, and the chelating agent or the bifunctional chelating agent is a macrocyclic compound, a bridged macrocyclic compound, a bicyclic compound, or an acyclic compound. 12. The composition of claim 11, wherein the bifunctional chelating agent is DOTA.